Position in CADL
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$765,938
+$473,756 QoQ
Shares Held
74,363
+24.7% QoQ
Ownership
0.097%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#39
of 138 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CADL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ALPS ADVISORS INC holds $213,436,831 across 115 Biotechnology names. CADL ranks #70 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
315,335 | $17,680,833 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
62,523 | $8,298,677 | |
| 3 | CGON |
CG Oncology, Inc.
|
89,218 | $6,338,938 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
97,610 | $5,891,739 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
61,014 | $5,806,702 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
55,281 | $5,388,791 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
93,981 | $5,339,060 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
110,388 | $5,192,651 |
All Filings in CADL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $765,938 | 74,363 | Shares | Defined | 2026-07-29 | |
| 2026-03-31 | $292,182 | 59,629 | Shares | Defined | 2026-05-08 | |
| 2025-12-31 | $254,696 | 45,079 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $134,017 | 26,278 | Shares | Defined | 2025-11-05 | |
| 2025-06-30 | $136,847 | 27,045 | Shares | Defined | 2025-08-11 | |
| No filing history on record for this holder in this stock. | ||||||